## Abstract We performed a 39‐week, randomized, double‐blind, multicenter study to compare the efficacy, safety, and tolerability of levodopa/carbidopa/entacapone (LCE, Stalevo) with levodopa/carbidopa (LC, Sinemet IR) in patients with early Parkinson's disease (PD). Four hundred twenty‐three patie
A double-blind comparison of levodopa, madopa, and sinemet in Parkinson disease
✍ Scribed by Dr. Shirley G. Diamond; Charles H. Markham; Leo J. Treciokas
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 549 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnific
## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi
Wearing-off' effect, the most common form of levodopa-induced fluctuations, seems to be related to the short plasma half-life of the drug. More sustained plasma levodopa levels may be achieved with a new controiledrelease formulation of carbidopdevodopa, Sinemet CR4. We studied 20 patients, 12 men a